Difference between atorvastatin and rosuvastatin
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Differences Between Atorvastatin and Rosuvastatin
Lipid-Lowering Efficacy
Both atorvastatin and rosuvastatin are high-intensity statins used to lower low-density lipoprotein cholesterol (LDL-C) levels. However, studies have shown that rosuvastatin tends to be more effective in reducing LDL-C levels compared to atorvastatin. For instance, in the POLARIS study, rosuvastatin 40 mg reduced LDL-C levels by 56%, while atorvastatin 80 mg reduced them by 52%. Similarly, a meta-analysis found that rosuvastatin provided greater reductions in total atheroma volume and percent atheroma volume compared to atorvastatin. Another study demonstrated that rosuvastatin 10 mg was more effective than atorvastatin 20 mg in reducing mild coronary atherosclerotic plaques.
Impact on Glucose Metabolism
The effects of atorvastatin and rosuvastatin on glucose metabolism have been a point of concern, especially in patients with diabetes. In a study involving Japanese hypercholesterolemic patients with diabetes, both statins had similar effects on non-high-density lipoprotein cholesterol (non-HDL-C) and HbA1c levels, although there was a tendency for more intensive diabetes therapy in the atorvastatin group. Another study found that both statins increased insulin levels, but atorvastatin also increased glycated albumin levels, indicating a potential adverse effect on glucose metabolism.
Safety and Adverse Effects
When it comes to safety, both atorvastatin and rosuvastatin are generally well-tolerated, but they have different profiles of adverse effects. In the LODESTAR trial, rosuvastatin was associated with a higher incidence of new-onset diabetes mellitus requiring antidiabetic medication and cataract surgery compared to atorvastatin. However, a meta-analysis found no significant differences in the rates of myalgia, elevated liver enzymes, or creatine kinase levels between the two statins.
Cardiovascular Outcomes
In terms of cardiovascular outcomes, both statins have shown comparable efficacy. The LODESTAR trial reported no significant difference in the composite outcome of all-cause death, myocardial infarction, stroke, or any coronary revascularization between the two statins over three years. Additionally, both statins were found to be equally effective in improving left ventricular function and reducing inflammatory biomarkers in type 2 diabetic patients with dyslipidemia.
Conclusion
In summary, while both atorvastatin and rosuvastatin are effective in lowering LDL-C levels and improving cardiovascular outcomes, rosuvastatin generally provides greater reductions in LDL-C and atheroma volume. However, rosuvastatin may have a higher risk of adverse effects such as new-onset diabetes and cataract surgery. The choice between these two statins should be based on individual patient profiles and specific clinical considerations.
Sources and full results
Most relevant research papers on this topic